Arcticzymes Technologies ASA
F:B4V
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.158
2.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| NO |
|
Arcticzymes Technologies ASA
OSE:AZT
|
1.2B NOK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.6B USD |
Loading...
|
Market Distribution
| Min | -4 257 300% |
| 30th Percentile | -4.2% |
| Median | 0.8% |
| 70th Percentile | 6.7% |
| Max | 82 378.7% |
Other Profitability Ratios
Arcticzymes Technologies ASA
Glance View
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Arcticzymes Technologies ASA is 7.4%, which is below its 3-year median of 11.3%.
Over the last 3 years, Arcticzymes Technologies ASA’s Net Margin has decreased from 31.8% to 7.4%. During this period, it reached a low of 2.2% on Mar 31, 2025 and a high of 31.8% on Sep 30, 2022.